Refine your search

Search Results within category "Lung Disease & Asthma"

Search all categories

Suggestions within category "Lung Disease & Asthma"


Study matches: 10

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.


Pulmonary Fibrosis Foundation Patient Registry and Biorepository

The aim of the registry is to create a cohort of well-characterized patients with interstitial lung disease (ILD) for participation in retrospective and prospective research.
Timothy Sheehan at tsheehan@pennstatehealth.psu.edu or 7175312925
All
18 year(s) or older
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
18 years old or older
Able to understand and sign informed consent document
Diagnosis of Interstitial Lung Disease
Anticipated appointment to Penn State Hershey Medical Center Pulmonary Clinic
Exclusion Criteria:
Diagnosed with Sarcoidosis
Diagnosed with Lymphangioleiomyomatosis (LAM)
Diagnosed with Pulmonary alveolar proteinosis (PAP)
Diagnosed with Cystic fibrosis (CF)
Diagnosed with Amyloidosis
Show full eligibility criteria
NCT02758808
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

INtervention Study In overweiGHT patients with COPD (INSIGHT COPD)

This study is testing the effectiveness of an evidence based, self-directed, lifestyle intervention for 12 months targeting modest weight loss and increased physical activity among overweight and obese patients with COPD. Randomized study to usual care vs usual care plus the self-directed program.
Timothy Sheehan at tsheehan@pennstatehealth.psu.edu or 7175312925
All
18 year(s) or older
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
40 years of age or older
Diagnosis of COPD
Body mass index (BMI) between 25.0-44.9
Smoked at least 10 pack-years of cigarettes
Access to DVD player or internet
Exclusion Criteria:
Active participation/use of weight loss interventions
Expected weight loss because of alternate explanations (i.e. illness)
Unable to walk to weight scale
Participation in other intervention studies
Show full eligibility criteria
NCT02634268
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Clinical Trial of Omalizumab in Patients With Chronic Rhinosinusitis With Nasal Polyps

This study is for patients with chronic rhinosinusitis and nasal polyps who have had an inadequate response to standard treatments to determine the effectiveness (good and bad) and safety of omalizumab (Xolair) compared with placebo (an inactive substance).
Terri Smith at tsmith@pennstatehealth.psu.edu or 717-531-4513
All
18 year(s) or older
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
18-75 years old
Diagnosed with nasal polyps
Chronic nasal congestion or blockage
Exclusion Criteria:
History of sinus or nasal surgery that altered the structure of the nose in the past 6 months
History of nasal surgery in the past 6 months
Uncontrolled nose bleeds requiring intervention
Nasal septal deviation of one or both nostrils
At least one of the following: nasal discharge or reduction/loss of smell
Show full eligibility criteria
NCT03280537
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Evaluating the Cough Reflex in Fibrotic and Healthy Lungs

Determining cough threshold in patients with fibrotic lung disease and in healthy controls by stimulating cough.
Timothy Sheehan at tsheehan@pennstatehealth.psu.edu or 7175312925
All
18 year(s) or older
This study is also accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
40 years of age or older
Patient Group: Fibrotic lung disease with chronic cough symptoms or Idiopathic cough syndrome
Healthy Control Group: no cough (either chronic or acute)
Exclusion Criteria:
Recent history of smoking (former smokers must be tobacco-free for at least 1 year)
History of (other) lung diseases
History of uncontrolled gastroesophageal reflux disease (GERD)
Use of exclusionary medications (i.e. steroids, ACE inhibitors, narcotics, cough suppressants)
History of uncontrolled post nasal drip
Show full eligibility criteria
N/A
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

VIOLET: Vitamin D to Improve Outcomes by Leveraging Early Treatment

To assess the efficacy and safety of early administration of vitamin D3 (cholecalciferol) in reducing mortality and morbidity for vitamin D deficient patients at high risk for Acute Respiratory Distress Syndrome (ARDS) and mortality.
Nancy Campbell RN at ncampbell1@pennstatehealth.psu.edu or 717-531-1707 ext. 3
All
18 year(s) or older
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
Admission to ICU with acute risk factors for Acute Respiratory Distress Syndrome (ARDS): Pneumonia, Aspiration, smoke inhalation, lung contusion, hypoxemia, intubation
shock
sepsis
pancreatitis
Vit. D deficiency
Exclusion Criteria:
unable to take Vit D by mouth
blood Calcium levels > 10.2
known kidney stone in past 1 year
Do Not Rescusitate orders (DNR)
prisoner
Show full eligibility criteria
NCT03096314
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

SAV005-04 "A Phase III, randomized, double-blind, placebo-controlled study of AeroVanc for the treatment of persistent methicillin-resistant Staphylococcus aureus lung infection in cystic fibrosis patients

This is a study that will examine any benefits to use cycles of inhaled vancomycin compared to placebo. Analysis of the information will include lung function results, sputum or throat culture results, questionnaires, and time to use additional antibiotics up to 48 weeks. After the first 24 weeks, all subjects can receive open label study drug for the remaining 24 weeks. There are 13 study visits spanned over 48 weeks.
Diane Kitch at dkitch@pennstatehealth.psu.edu or 7175315646
All
All
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
6 years old and greater
Must have Cystic Fibrosis (CF)
Positive culture for MRSA at screening
FEV1 between 30-90%
Commit to 14 visits over 12 months
Exclusion Criteria:
You may not have allergies to vancomycin
Abnormal liver or kidney function
Inability to tolerate inhaled products
Show full eligibility criteria
NCT03181932
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Establishing a Normal Database for Comparison to Specialized Populations; Pulmonary Function Tests

This study will evaluate lung function by measuring volumes, flow, capacity and other variables by completing various breathing tests into a machine. This will contribute to a database of healthy adults to compare to persons with disabilities.
Kristin Slavoski at PMR_Research@pennstatehealth.psu.edu or 717-531-0003
All
18 year(s) or older
This study is also accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
Healthy Adults
Age 18-75
Exclusion Criteria:
Known cardiovascular, pulmonary or metabolic disease
Pregnancy
High Blood Pressure
Show full eligibility criteria
N/A
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Randomized, Placebo-Controlled, Double-Blind, Six Months Study Followed by an Open-Label -Extension Phase to Evaluate the Efficacy, Safety and Tolerability of MN-001 in Subjects with Idiopathic Pulmonary Fibrosis (IPF)

The purpose of this research study is to evaluate the effectiveness and safety of MN-001(tipelukast) in subjects with IPF.
Kim Hitz at khitz1@pennstatehealth.psu.edu or 7175667765
All
18 year(s) or older
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
diagnosis of pulmonary fibrosis
presence of stage I-III defined by GAP index
Exclusion Criteria:
expected to receive a lung transplant in the next 12 months
known explanation for interstitial lung disease
ongoing treatment with Esbriet
Show full eligibility criteria
NCT02503657
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A double-blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nintedanib over 52 weeks in patients with progressive fibrosing interstitial lung disease (PF-ILD)

This study is for patients who have progressive fibrosing interstitial lung disease (PF-ILD) to see how well an investigational medicine called nintedanib, may help this lung disease. The study will also compare the safety and effects of the investigational medicine with a placebo (a pill without medication).
Anne Dimmock at adimmock@pennstatehealth.psu.edu or 717-531-2925
All
18 year(s) or older
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
Patients diagnosed with pulmonary fibrosis interstitial lung disease
Exclusion Criteria:
Patients with underlying chronic liver disease
Previous treatment with nintedanib or pirfenidone
Significant pulmonary arterial high blood pressure
High Blood Pressure, Heart Attack or Unstable Chest pain within the past 6 months
Have an increased risk of bleeding
Show full eligibility criteria
NCT02999178
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Study of Clinical Efficacy of Antimicrobial Therapy Strategy Using Pragmatic Design in Idiopathic Pulmonary Fibrosis

This study is for patients with Idiopathic Pulmonary Fibrosis (IPF) to compare the effect of standard care versus standard care plus antibiotic therapy (co-trimoxazole or doxycycline) on reducing harmful infections that could lead to hospital visits or death in patients diagnosed with IPF.
Tim Sheehan at tsheehan@pennstatehealth.psu.edu or 717-531-2925
All
18 year(s) or older
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
Must be 40 years of age or older
Diagnosed with Idiopathic Pulmonary Fibrosis
Exclusion Criteria:
Received antimicrobial therapy in the past 30 days
Allergy or intolerance to tetracycline
Concomitant immunosuppression with azathioprine, mycophenolate, cyclophosphamide or cyclosporine
Received treatment with an investigational medication in the past 30 days
Show full eligibility criteria
NCT02759120
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA